But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

New Jersey’s pharma sector faces new layoffs as Merck cuts 204 jobs and Bristol Myers Squibb plans 110 reductions amid cost-saving efforts.

>40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is developing ...

Shares of Merck & Company are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer.

Merck & Co (NYSE:MRK) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

German science and technology company Merck KGaA has launched a supercomputer in Germany. Housed in an Equinix data center in ...